SCHEMBL7141828

SCHEMBL7141828

Brc1cccc(-c2c[nH]c(-c3ccccc3)n2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.55
MAPT P10636 4/20 0.55
ALDH1A1 P00352 3/20 0.55
HPGD P15428 3/20 0.55
RAB9A P51151 3/20 0.55
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
NPC1 O15118 2/20 0.55
TSHR P16473 2/20 0.55
HTT P42858 2/20 0.55
IDO1 P14902 2/20 0.47
METAP2 P50579 1/20 0.47
DCUN1D1 Q96GG9 2/20 0.46
GAA P10253 2/20 0.46
HK1 P19367 1/20 0.46
HKDC1 Q2TB90 1/20 0.46
ALOX15 P16050 1/20 0.46
ALOX12 P18054 1/20 0.46
MPI P34949 1/20 0.46
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27762174 0.95 RAB9A (0.50) SMN1; SMN2MAPTALDH1A1HPGDRAB9A
SCHEMBL17279780 0.87 MEN1 (0.43) SMN1; SMN2MAPTALDH1A1HPGDRAB9A
SCHEMBL8110189 0.86 ADORA2A (0.49) SMN1; SMN2MAPTALDH1A1HPGDRAB9A
SCHEMBL7139439 0.84 DGAT1 (0.51) SMN1; SMN2MAPTALDH1A1RAB9AMEN1
SCHEMBL7143721 0.84 DGAT1 (0.51) SMN1; SMN2MAPTALDH1A1RAB9AMEN1
SCHEMBL528246 0.83 MEN1 (0.46) SMN1; SMN2MAPTALDH1A1HPGDRAB9A
SCHEMBL8131055 0.82 NPC1 (0.43) SMN1; SMN2MAPTALDH1A1HPGDRAB9A
SCHEMBL17279786 0.82 MEN1 (0.46) SMN1; SMN2MAPTALDH1A1HPGDRAB9A
SCHEMBL27762157 0.81 MAPK13 (0.49) SMN1; SMN2MAPTHPGDMEN1KMT2A
SCHEMBL22038617 0.81 PDGFRB (0.48) MAPTALDH1A1HPGDRAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6515133-B1 Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. NEUROGEN CORPORATION 2003-02-04 US claimed
CN-1265033-A Certain diarylimidaozle derivatives, new class of NPY speific ligands NEUROGEN CORP (US) 2000-08-30 CN claimed
EP-0996443-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 2000-05-03 EP claimed
WO-1999001128-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1999-01-14 WO claimed
CN-101448978-B Surface treating agent for metal and use thereof SHIKOKU CHEM 2012-06-13 CN disclosed
CN-101448978-A Surface treating agent for metal and use thereof SHIKOKU CHEM (JP) 2009-06-03 CN disclosed
US-6515133-B1 Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. NEUROGEN CORPORATION 2003-02-04 US disclosed
US-6121260-A Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives NEUROGEN CORPORATION (US) 2000-09-19 US disclosed
CN-1265033-A Certain diarylimidaozle derivatives, new class of NPY speific ligands NEUROGEN CORP (US) 2000-08-30 CN disclosed